Sprout Health Review

The structure is sound

Sprout Health Partners LLC is a real company with a physical address in Encinitas, California. It is LegitScript-certified, prescribing runs through MD Integrations — an identifiable third-party clinician network rather than an anonymous in-house panel — and fulfilment goes through US 503A compounding pharmacies. It offers genuine brand-name Wegovy and Zepbound as well as compounded products, and its terms allow you to nominate a different licensed pharmacy. None of this is a company operating in the shadows, and the medication does appear to be real and to reach most customers.

On the public review scores

We looked for a reliable consumer score and could not settle on one. Different sources report materially different Trustpilot figures for Sprout Health, on a small review base, so quoting any single number would be misleading. We have therefore leaned on the BBB data, which we verified directly against the BBB profile, and on the consistency of the complaint themes across three independent platforms. If you want to check for yourself before buying, the BBB complaint file is the most substantive public record.

What to check before you buy

• •Get the exact monthly price in writing — $99, $149 and $299 all appear in different places
• •Get the cancellation procedure in writing before you pay, given how often cancellation is the complaint
• •Pay with a card that gives you a straightforward dispute route
• •Confirm the dose on the vial matches the dose you were prescribed on arrival
• •Ask which pharmacy is filling your order, and consider nominating your own
• •Ask what clinical basis supports compounding for you, now that neither drug is in shortage

Did Sprout Health really get an FDA warning letter?

Yes. On 9 September 2025 the FDA issued Sprout Health Partners LLC a warning letter, reference 715879, after reviewing its website in August 2025. The agency objected to the statement that 'GLP-1 medications are FDA-approved and backed by extensive clinical research' appearing in connection with compounded semaglutide and tirzepatide. The FDA's position was direct: compounded drug products are not FDA-approved, the claim implies the products are the same as an approved product when they are not, and the products were therefore misbranded. The letter cited sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act, and section 301(a) for introducing misbranded products into interstate commerce. Sprout was given 15 working days to respond, and the FDA warned that failure to correct could lead to seizure or injunction without further notice. Sprout was one of roughly 80 companies to receive letters in that September 2025 wave.

Has the company fixed the problem?

On the specific wording, it appears so, and it is only fair to say that. When we checked the site on 7 August 2026, it carried the correct disclaimer: 'Compounded GLP-1 and GIP/GLP-1 are not approved by the FDA and have not been evaluated for safety, effectiveness, or quality by the FDA.' That is the right statement and it directly addresses what the FDA cited. What a corrected sentence does not fix is the service record, which is a separate and arguably more consequential problem — see the BBB position below.

What does the BBB say?

This is the finding that most affects our rating. The Better Business Bureau lists Sprout Health as not accredited and rates it F, giving the reason as 'Failure to respond to 32 complaint(s) filed against business' out of 64 complaints filed in total. BBB records the business start date as 29 January 2025. That means roughly 64 formal complaints accumulated in about eighteen months of trading, and the company left half of them unanswered. An F for non-response is not proof that the medication is substandard, and BBB accreditation is voluntary. What it does show is that when customers escalated a problem, in half the cases nobody engaged with them.

What do customers actually complain about?

The pattern is consistent enough across BBB, ConsumerAffairs and Trustpilot to treat as real. Unreachable customer service is the single most common theme — unreturned voicemails and unanswered emails. Beyond that, three specific failures recur: medication paid for but never delivered; the wrong dose being sent; and cancellation being extremely difficult, with several customers saying they had to go through their credit card company to stop the billing. The public Trustpilot record is thin and sources disagree on the exact score, so we are not going to quote a number we cannot pin down — the BBB figures above are the ones we verified directly and they tell a clear enough story.

How much does it cost?

Checked on 7 August 2026, Sprout advertised compounded semaglutide from $149/month and compounded tirzepatide from $199/month, with brand-name Wegovy listed around $1,579 and Zepbound around $1,249 as cash prices. But the figures are not consistent across the funnel: 'personalized GLP-1 care from $99 first month' also appears, and some members report being billed a flat $299 each month. That spread — $99, $149, $299 — is wide enough that we would not rely on the headline. The company does advertise one genuinely useful thing: price locked as you titrate up, so moving to a higher dose should not increase the bill. Get your specific monthly figure and your renewal price in writing before you pay, and given the cancellation complaints, note the exact steps required to stop the subscription at the same time.

Where is it available?

Not everywhere, and the exclusions are specific. Compounded semaglutide, compounded tirzepatide and semaglutide are not available in Alabama, Arkansas, Louisiana, Mississippi or North Dakota. NAD+ injections are separately unavailable in California. It is a United States service only. Because state telehealth and compounding rules change, confirm your own state at intake rather than relying on this list.

Are the medications FDA-approved?

The compounded ones are not — that is the whole substance of the FDA's warning letter. Compounded semaglutide and tirzepatide are prepared by licensed compounding pharmacies for patient-specific prescriptions. They are not FDA-approved, are not evaluated by the FDA for safety, effectiveness or quality, and are not equivalent to Ozempic, Wegovy, Mounjaro or Zepbound beyond sharing an active ingredient. Sprout does also offer genuine brand-name Wegovy and Zepbound, which are FDA-approved — but at listed cash prices well over $1,000 a month. Since neither semaglutide nor tirzepatide is currently in shortage, ask what clinical basis supports compounding in your particular case.

Who should not use these medications?

GLP-1 receptor agonists are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in anyone who has had a serious allergic reaction to the medication. They should not be used in pregnancy, while trying to conceive, or while breastfeeding. Common side effects are nausea, vomiting, diarrhoea and constipation, usually worst during dose escalation; more serious risks include pancreatitis, gallbladder disease and kidney injury. Anyone with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, diabetic retinopathy or kidney impairment should discuss those specifically with a clinician first. This page is information, not medical advice.

How much weight might I lose?

No provider can promise an outcome, and Sprout's marketing language about GLP-1s being 'a genuine game-changer' is advertiser copy, not evidence. For context from trials of the approved branded products: in STEP 1, adults with overweight or obesity without diabetes taking semaglutide 2.4 mg weekly with lifestyle support lost a mean 14.9% of body weight at 68 weeks, versus 2.4% on placebo (Wilding et al., New England Journal of Medicine, 2021). In SURMOUNT-1, tirzepatide 15 mg produced a mean 20.9% reduction at 72 weeks versus 3.1% on placebo. Both trials ran well over a year and studied the approved branded injectables, not compounded preparations.